OncoMatch/Clinical Trials/NCT07807696
Olive Oil Before Lung Cancer Surgery to Prevent Chylothorax
Official title: A Multicenter, Prospective, Randomized Controlled Trial of Preoperative Oral Olive Oil for the Prevention of Postoperative Chylothorax in Patients With Lung Cancer
Is NCT07807696 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for lung cancer.
Chylothorax is a rare but serious complication after lung cancer surgery and mediastinal lymph node dissection. This multicenter randomized trial will evaluate whether drinking 40 mL of extra-virgin olive oil 4 hours before surgery can reduce the occurrence of chylothorax after curative lung cancer resection. A total of 1,036 adults with resectable lung cancer will be assigned in a 1:1 ratio to preoperative oral olive oil or standard preoperative fasting without additional olive oil. The primary outcome is the occurrence of chylothorax within 30 days after surgery. Secondary outcomes include repeat surgery, postoperative complications, chest drainage, length of chest tube use, length of hospital stay, and the safety and tolerability of the intervention.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: surgery for lung cancer
No prior surgery for lung cancer
Cannot have received: radiotherapy
no prior radiotherapy or chemotherapy
Cannot have received: chemotherapy
no prior radiotherapy or chemotherapy
Cannot have received: ipsilateral thoracic surgery
Prior ipsilateral thoracic surgery
Cannot have received: thoracic radiotherapy
Prior thoracic radiotherapy
Cannot have received: thoracic chemotherapy
Prior thoracic chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07807696 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify